Innovations in Combining SBRT and Systemic Treatments for Urological Cancers
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 78
Special Issue Editor
Special Issue Information
Dear Colleagues,
Stereotactic Body Radiation Therapy (SBRT) has emerged as a promising treatment modality for urological cancers, offering precise delivery of high-dose radiation to tumors while minimizing damage to surrounding healthy tissues. Systemic treatments, including immunotherapy, chemotherapy, and targeted agents, play a crucial role in combating urological cancers by addressing cancer cells throughout the body. Additionally, ablative radiation (> 45 Gy) delivered in 15-25 courses, though not strictly SBRT, presents another effective treatment approach. The integration of these systemic approaches with SBRT and ablative radiation holds the potential to revolutionize treatment paradigms, offering enhanced therapeutic outcomes and improved quality of life for patients. Covering a spectrum of urological malignancies including prostate, bladder, kidney, and testicular cancers, this issue aims to showcase innovative strategies that integrate SBRT, ablative radiation, and various systemic therapies. By exploring the synergies between localized radiation therapies and systemic treatments, this collection anticipates shedding light on novel approaches that may redefine treatment standards in urologic oncology. Authors are encouraged to submit research that elucidates the potential benefits, challenges, and future directions of combining these radiation therapies with systemic interventions for urological cancers.
Dr. Steven N. Seyedin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- urological cancers
- stereotactic body radiation therapy (SBRT)
- systemic treatments
- ablative radiation
- immuno-therapy
- chemotherapy
- targeted agents
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
